What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — 15 amino acids — originally isolated from human gastric juice. The parent protein, BPC, has long been known to protect the gastrointestinal mucosa, but the 157-amino acid fragment identified in research settings shows the most pronounced systemic activity. It is stable in human gastric juice, resistant to enzymatic degradation, and has been studied in both local and systemic injection models.
Primary Mechanism: Angiogenesis & Growth Factor Upregulation
BPC-157's best-documented mechanism is the upregulation of VEGF (vascular endothelial growth factor) and the nitric oxide (NO) pathway. By promoting angiogenesis — the formation of new blood vessels — BPC-157 accelerates nutrient and oxygen delivery to injured tissue. Studies in tendon, muscle, ligament, and bone models consistently show accelerated fibroblast migration and collagen synthesis at injury sites following local administration. Importantly, BPC-157 also upregulates the GH receptor in tendon fibroblasts, which provides a secondary healing signal independent of exogenous growth hormone.
Local vs. Systemic Administration in Research
Most peer-reviewed BPC-157 research uses intramuscular or subcutaneous injection proximal to the injury site. This local administration model produces the strongest tissue-specific effects. However, oral administration has also been studied for gastrointestinal models, and intraperitoneal injection appears effective for systemic anti-inflammatory research. The choice of route in research design significantly affects which tissues receive the most exposure.
COA Standards for BPC-157
BPC-157 at 15 amino acids is straightforward to verify by HPLC and mass spectrometry. Researchers should expect HPLC purity ≥99.0% with a single dominant peak corresponding to the correct retention time. Mass spectrometry should confirm a molecular weight of approximately 1,419.5 Da (the exact value varies slightly by salt form). Any COA showing purity below 98% or lacking MS identity confirmation should be considered insufficient for research use.
Key Research Findings
Published animal studies have demonstrated BPC-157 activity in rotator cuff repair, Achilles tendon transection models, colitis models, and traumatic brain injury models. The compound has shown a strong safety profile across doses used in animal research, with no LD50 established in rodent studies. Human clinical data is limited — BPC-157 has not completed Phase 3 trials in any indication — making animal and in vitro data the primary reference point for researchers.